Chinese manufacturers struggle to transition lab innovations into commercial-scale production

Chinese biotech, pharmaceutical, and advanced manufacturing companies have breakthrough innovations stuck in laboratory phases but lack access to mid-stage pilot production (zhong shi) platforms to validate scalability and economics before full commercialization. Current solutions are fragmented, expensive, and geographically concentrated, forcing companies to either build proprietary facilities (massive capex) or abandon promising technologies, directly blocking the development of new productive forces (xin zhi sheng chan li) that Beijing's economic strategy depends on.